November 6, 2025

Q3 2025 Results

Clinical Trial Appendix

Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding BeOne's research, discovery, pre-clinical and clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeOne undertakes no duty to update such information unless required by law.

BeOne pipeline snapshot

As of: 23 Oct 2025

40+
Clinical and commercial stage assets

75+
Approvals for BRUKINSA® (zanubrutinib) in countries globally

45+
Approvals for TEVIMBRA® (tislelizumab) in countries globally

175+
Total clinical trials conducted

30,000+
Patients enrolled in clinical trials globally*

Across three therapy areas:







* Including IITs

Project movements since Q2 2025 update

As of: 23 Oct 2025

New to Phase I/Ib	New to Phase II	New to Pivotal Trial	Accepted Submission *Select markets* *(AUS, US, BR, CA, CN, EU, JP, UK)*	Approved *Select markets* *(AUS, US, BR, CA, CN, EU, JP, UK)*
BTKi + BCL2i BG-71332-101 Relative bioavailability[1]	**IRAK4 CDAC** BGB-45035-201 Rheumatoid arthritis		**Tislelizumab** (312 SCLC) in AUS (305 1L GC) in JP	**Zanubrutinib 114** (Tablet Formulation) in EU
EGFR x MET x MET ADC BG-C0902-101 Solid tumors[1]	**Blinatumomab** 20180257 R/R and MRD+ B-ALL (SubQ)			**Tislelizumab** (305 1L GC) in BR (306 1L ESCC) in BR, UK (309 1L NPC) in EU (315 Neo-Adj/Adj NSCLC) in EU (Alt Dosing Q2W /Q4W) in AUS

[1]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled
AUS – Australia; BR – Brazil; EU – European Union; JP – Japan; UK – United Kingdom

Projects removed since Q2 2025 update

As of: 23 Oct 2025

Removed from Phase I	Removed from Phase II	Removed from Phase III
	BGB-A317-203 (Tislelizumab) 3L cHL[1]	**BGB-A317-314** (Tislelizumab) R/R cHL[1]

[1] Confirmatory trial for accelerated approval Indication; indication has been withdrawn in China

Global clinical development pipeline

Updated: 05 Nov 2025

Phase 1

Sonrotoclax — BCL2i
- 101 B-cell malignancies
- 102 B-cell malignancies
- 103 AML/MDS
- 105 R/R MM t(11;14)
- 108 Dose ramp-up

BGB-16673 — BTK CDAC
- 101 B-cell malignancies
- 102 B-cell malignancies
- 104 B-cell malignancies
- 107 Chronic spontaneous urticaria

BG-71332 — BTKi + BCL2i
- 101 Relative bioavailability

BGB-21447 — BCL2i
- 101 B-cell malignancies
- 102 HR+ Breast cancer

BGB-43395 — CDK4i
- 101/102 BC and solid tumors

BG-C9074[1] — B7-H4 ADC
- 101 BC and solid tumors

BG-68501[2] — CDK2i
- 101 BC and solid tumors

BGB-A3055 — CCR8 mAb
- 101 Solid tumors/pan-tumor

BGB-B455 — CLDN 6 x CD3 BsAb
- 101 Gyn. and solid tumors

BG-75202 — KAT6A/Bi
- 101 BC and solid tumors**

BGB-58067 — MTA Coop. PRMT5i
- 101 Lung and Solid Tumors

BG-89894[3] — MAT2Ai
- 101 Lung and Solid Tumors

BG-60366 — EGFR CDAC
- 101 Lung cancers

BG-T187 — EGFR x MET x MET TsAb
- 101 Lung and GI Cancers

BGB-C354 — B7-H3 ADC
- 101 Solid tumors

BGB-R046 — IL-15 prodrug
- 101 Solid tumors/pan-tumor

BGB-26808 — HPK1i
- 101 Solid tumors/pan-tumor

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20240124 2L+ SCLC (+B7-H3)
- 20230298 2L+ SCLC SubQ**

BG-C0902 — EGFR x MET x MET ADC
- 101 Lung and GI cancers**

BGB-53038 — Pan-KRASi
- 101 Lung and GI cancers

BG-C477 — CEA ADC
- 101 Lung and GI cancers

BG-C137 — FGFR2b ADC
- 101 GI cancers

BGB-B3227 — MUC1 x CD16A BsAb
- 101 Solid tumors

BGB-B2033 — GPC3 x 4-1BB BsAb
- 101 Solid tumors

Xaluritamig[4] — STEAP1 x CD3 XmAb®
- 20180146 mCRPC

BGB-45035 — IRAK4 CDAC
- 101 Immunology and Inflammation

Phase 2

Sonrotoclax — BCL2i
- 201 R/R MCL
- 203 R/R WM
- 204 TN CLL/SLL

BGB-16673 — BTK CDAC
- 101 R/R CLL and R/R WM
- 102 R/R CLL

Blinatumomab[4] — CD19 x CD3 BiTE®
- 20180257 R/R B-ALL SubQ, MRD+

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20240092 2L SCLC (Alt dosing)

BGB-45035 — IRAK4 CDAC
- 201 Rheumatoid Arthritis

Phase 3

Zanubrutinib — BTKi
- 306 TN MCL
- 308 R/R MZL, R/R FL
- 309 pMN

Sonrotoclax — BCL2i
- 301 TN CLL
- 302 R/R MCL
- 303 R/R CLL/SLL

BGB-16673 — BTK CDAC
- 302 R/R CLL
- 303 R/R CLL/SLL
- 304 R/R CLL/SLL (vs. Pirto)

Pamiparib — PARPi
- 302 2L PSOC Mtx

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20200041 1L ES-SCLC MTx
- 20240178 1L ES-SCLC Ind. and MTx
- 20230016 LS-SCLC

Zanidatamab[5] — HER2 BsAb
- 301 1L HER2+ GEA

Tislelizumab — PD-1 mAb
- 310 1L UBC
- 316 SubQ

Accepted submissions
Major markets (US, CN, EU, JP)

Sonrotoclax — BCL2i
- 201 R/R MCL (CN)
- 202 R/R CLL (CN)

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20230273 3L+ SCLC (CN)
- 20210004 2L SCLC (CN)

Tislelizumab — PD-1 mAb
- 305 1L GC (JP)
- Alternate dosing Q6W (U.S.)

- Hematology
- Lung
- Breast / Gynecological
- Gastrointestinal
- Other cancers
- Immunology and Inflammation

[1] DualityBio collaboration, [2] Ensem collaboration, [3] CSPC collaboration, [4] Amgen collaboration, [5] Zymeworks/Jazz collaboration
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details
** Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Our pipeline includes diverse modalities and mechanisms across disease franchises

As of: 23 Oct 2025

Breast/Gynecologic

- CDK4i
- CDK2i
- BCL2i
- KAT6A/Bi[1]
- B7-H4 ADC
- Claudin 6 x CD3 BsAb
- CDK2 CDAC[1]
- CCR8 mAb[2]

Lung

- Pan-KRASi
- MTA Cooperative PRMT5i
- MAT2Ai
- CEA ADC
- B7-H3 ADC
- EGFR CDAC
- EGFR x MET x MET TsAb
- EGFR x MET x MET ADC[3]
- HPK1i[2]
- IL-15 prodrug[2]

Gastrointestinal

- Pan-KRASi
- MTA Cooperative PRMT5i
- MAT2Ai
- FGFR2b ADC
- CEA ADC
- GPC3 x 4-1BB BsAb
- MUC1 x CD16A BsAb

Small molecule | Protein degrader | Bi/Tri-specific | mAb | ADC | Cytokine therapy

[1] Not yet in Clinic, [2] Pan-tumor, [3] Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Target(i), target inhibitor; CDAC, chimeric degradation activating compound; ADC, antibody drug conjugate; BsADC, bispecific ADC; TsADC, trispecific ADC; BsAb, bispecific antibody; TsAb, trispecific antibody

BeOne has global rights for CDK2i (Ensem partnership), B7-H4 ADC (DualityBio partnership), MAT2Ai (CSPC Zhongqi Pharmaceutical Technology)

Building leadership in solid tumors with innovative NMEs

As of: 23 Oct 2025

	Phase 1	Phase 2	Phase 3
Breast/ Gynecologic Cancers	**BGB-C9074-101** **B7-H4-ADC** Breast (other ST) **BGB-43395-101/102** **CDK4i** Breast (other ST) **BGB-21447-102** **BCL2i** Breast **BG-68501-101** **CDK2i** Breast (other ST) **BGB-B455-101** **Claudin 6 x CD3 BsAb** Gyn (other ST) **BGB-A3055-101** **CCR8 MAb** Solid Tumors/Pan-tumor		
Gastro-intestinal	**BG-53038-101** **Pan-KRASi** GI and lung **BGB-B2033-101** **GPC3 x 4-1BB BsAb** Solid Tumors **BG-C137-101** **FGFR2b ADC** GI **BGB-B3227-101** **MUC1 x CD16A BsAb** GI and Lung **BG-C477-101** **CEA ADC** GI and Lung		
Lung	**AMG757 20240124** **Tarlatamab DLL3 x CD3 BiTE®** 2L+ SCLC (+B7-H3) (Global) **AMG757 20230298** **Tarlatamab DLL3 x CD3 BiTE®** 2L+ SCLC (SubQ)[1] (Global) **BGB-C354-101** **B7-H3 ADC** Lung, GI and HNSCC **BG-T187-101** **EGFR x MET x MET TsAb** Lung and GI **BG-60366-101** **EGFR-CDAC** Lung **BGB-58067-101** **MTA-coop PRMT5i** Lung and Solid Tumors **BG-89894-101** **MAT2Ai** Lung and Solid Tumors **BG-C0902-101** **EGFR x MET x MET ADC** Lung and GI[1] **BGB-26808-101** **HPK1i** Solid Tumors/Pan-tumor **BGB-R046-101** **IL-15 prodrug** Solid Tumors/Pan-tumor	**AMG757 20240092** **Tarlatamab DLL3 x CD3 BiTE®** 2L+ SCLC (Alt dosing) (Global) **AMG757 20230273** **Tarlatamab DLL3 x CD3 BiTE®** 3L+ SCLC (CN)	**AMG757 20210004** **Tarlatamab DLL3 x CD3 BiTE®** 2L SCLC (Global) **AMG757 20230016** **Tarlatamab DLL3 x CD3 BiTE®** LS-SCLC (Global)
Other	**AMG509 20180146** **Xaluritamig STEAP1 x CD3 XmAb®** mCRPC (Global)		

Studies in "close-out" status excluded

[1]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Refer to Glossary abbreviations

Building leadership in solid tumors with LCM

As of: 23 Oct 2025

	Phase 1	Phase 2	Phase 3	Approved[1]		
Breast/ Gynecologic Cancers			**BGB-290-302** **Pamiparib PARPi** 2L PSOC	**BGB-290-102** **Pamiparib PARPi** 3L+ PSOC, PROC	**Baituowei (Goserelin)** Breast, Prostate	
Gastro-intestinal		**BGB-A317-209** **Tislelizumab PD-1 mAb** Resect MSI-H/ dMMR CRC	**ZWI-ZW25-301** **Zanidatamab HER2 mAb** 1L HER2+ GEA	**BGB-A317-301** **Tislelizumab PD-1 mAb** 1L HCC	**BGB-A317-302** **Tislelizumab PD-1 mAb** 2L ESCC	**BGB-A317-305** **Tislelizumab PD-1 mAb** 1L GC
				BGB-A317-306 **Tislelizumab PD-1 mAb** 1L ESCC	**BGB-A317-208** **Tislelizumab PD-1 mAb** 2L/3L+HCC	**ZWI-ZW25-203** **Zanidatamab HER2 BsAb** HER2+ 2L+ BTC (CN)[2]
Lung				**BGB-A317-304** **Tislelizumab PD-1 mAb** 1L Non-sq. NSCLC	**BGB-A317-307** **Tislelizumab PD-1 mAb** 1L Sq. NSCLC	**BGB-A317-303** **Tislelizumab PD-1 mAb** 2/3L NSCLC
				BGB-A317-312 **Tislelizumab PD-1 mAb** 1L ES-SCLC	**BGB-A317-309** **Tislelizumab PD-1 mAb** 1L NPC	**BGB-A317-315** **Tislelizumab PD-1 mAb** Neo/adj. NSCLC
Other			**BGB-A317-310** **Tislelizumab PD-1 mAb** 1L UBC	**BGB-A317-290-LTE1** **Multiple assets** LTE Solid Tumors	**BGB-A317-204** **Tislelizumab PD-1 mAb** 2L UC	**BGB-A317-209** **Tislelizumab PD-1 mAb** Late Line MSI-H or dMMR
			BGB-A317-316 **Tislelizumab PD-1 mAb** SubQ Formulation			

Studies in "close-out" status excluded
[1]Approved in at least one major market, such as US, CN, EU, and/or JP
[2]Conditional approval
Refer to Glossary abbreviation

A leader in hematology / I&I portfolio – innovative NMEs

As of: 23 Oct 2025

	Phase 1			Phase 2		Phase 3	
AML/MDS, Multiple Myeloma, Other Heme	**BGB-11417-103** **Sonrotoclax BCL2i** AML/MDS	**BGB-11417-105** **Sonrotoclax BCL2i** R/R Multiple Myeloma t(11;14)	**BG-71332-101** **BCL2i+BTKi co-form.** Healthy volunteers				
B-Cell	**BGB-21447-101** **BCL2i** B-Cell Malignancies			**BGB-11417-201** **Sonrotoclax BCL2i** R/R MCL	**BGB-11417-202** **Sonrotoclax BCL2i** CLL/SLL (CN)	**BGB-11417-301** **Sonrotoclax BCL2i** TN CLL combo + zanu	**BGB-16673-302** **BTK CDAC** R/R CLL
	BGB-11417-102 **Sonrotoclax BCL2i** B-Cell Malig.(CN)	**BGB-11417-101** **Sonrotoclax BCL2i** mono & combo w/ zanu	**BGB-11417-108** **Sonrotoclax BCL2i** B-Cell Malig. dose ramp-up	**BGB-11417-203** **Sonrotoclax BCL2i** R/R WM	**BGB-11417-204** **Sonrotoclax BCL2i** TN CLL	**BGB-11417-302** **Sonrotoclax BCL2i** R/R MCL	**BGB-16673-303** **BTK CDAC** R/R CLL (CN)
	BGB-16673-101 **BTK CDAC** B-Cell Malig.	**BGB-16673-102** **BTK CDAC** B-Cell Malig. (CN)	**BGB-16673-104** **BTK CDAC** B-Cell Malig. combos	**BGB-16673-101/102** **BTK CDAC** R/R CLL & R/R WM (exp.)		**BGB-11417-303** **Sonrotoclax BCL2i** R/R CLL/SLL	**BGB-16673-304** **BTK CDAC** R/R CLL v. pirtobrutinib
I&I	**BGB-45035-101** **IRAK4 CDAC** HV & AD, PN	**BGB-16673-107** **BTK CDAC** Chronic Spontaneous Urticaria		**BGB-45035-201** **IRAK4 CDAC** RA			

Studies in "close-out" status excluded
Refer to Glossary abbreviation

A leader in hematology / I&I with LCM

As of: 23 Oct 2025

	Phase 1	Phase 2	Phase 3	Approved[1]
AML/MDS, Multiple Myeloma, Other Heme		**BLINCYTO®** **CD19 x CD3 BiTE** R/R and MRD+ B-ALL (Subq)		
B-Cell		**BGB-3111-304** **Zanubrutinib BTKi** TN CLL Ven combo	**BGB-3111-306** **Zanubrutinib BTKi** TN MCL **BGB-3111-LTE1** **Zanubrutinib BTKi** B-cell malignancies **BGB-3111-308** **Zanubrutinib BTKi** R/R MZL, R/R FL	**BGB-3111-206** **Zanubrutinib BTKi** R/R MCL **BGB-3111-212** **Zanubrutinib BTKi** R/R FL **BGB-3111-214** **Zanubrutinib BTKi** R/R MZL **BGB-3111-114** **Zanubrutinib BTKi** Tablet formulation **BGB-3111-302** **Zanubrutinib BTKi** TN & R/R WM **BGB-3111-304** **Zanubrutinib BTKi** TN CLL/SLL **BGB-3111-305** **Zanubrutinib BTKi** R/R CLL/SLL
I&I			**BGB-3111-309** **Zanubrutinib BTKi** PMN	

Studies in "close-out" status excluded
Refer to Glossary abbreviation
Blincyto 20190359 (post marketing) is not included in this view
[1]Approved in at least one major market, such as US, CN, EU, and/or JP

Trial detail

- **BRUKINSA®**(zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **Other Hematology Assets**
- **TEVIMBRA®** (tislelizumab)
- **Other Solid Tumor Assets**
- **Immunology and Inflammation Assets**

BRUKINSA®

Foundational asset in hematology portfolio

As of: 23 Oct 2025

Trial	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-111	**Phase 1/2**	NCT04172246	B-Cell Malignancies	55 (JP)	-	TEAEs and ORR	Closeout
BGB-3111-215	**Phase 2**	NCT04116437	Previous BTKi Tx - ibru/acala intolerant	96	-	TEAEs	Closeout
BGB-3111-304 (SEQUOIA)	**Phase 3**	NCT03336333	TN CLL/SLL	784	Venetoclax (arm D)	PFS	Approved[2] / Maint. (arm D)
BGB-3111-306 (MANGROVE)	**Phase 3**	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308 (MAHOGANY)	**Phase 3**	NCT05100862	R/R MZL and FL	780	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-LTE1	**Phase 3**	NCT04170283	B-Cell Malignancies	955		TEAEs	Maintenance
BGB-3111-114	**Phase 1**	NCT05767398	Healthy volunteers	58	-	PK	Approved[2]
BGB-3111-206	**Phase 2**	NCT03206970	R/R MCL	86	-	ORR	Approved[2]
BGB-3111-212 (ROSEWOOD)	**Phase 2**	NCT03332017	R/R FL	217	Obinutuzumab	ORR	Approved[2]
BGB-3111-214 (MAGNOLIA)	**Phase 2**	NCT03846427	R/R MZL	68	-	ORR	Approved[2]
BGB-3111-302 (ASPEN)	**Phase 3**	NCT03053440	TN & R/R WM	229	-	CR\VGPR	Approved[2]
BGB-3111-305 (ALPINE)	**Phase 3**	NCT03734016	R/R CLL	652	-	ORR	Approved[2]

Brukinsa® zanubrutinib

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Approved in at least one major market, such as the US, EU, China and/or Japan
Refer to Glossary abbreviations

Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

As of: 23 Oct 2025

Trial	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-11417-101	**Phase 1**	NCT04277637	B-Cell Malignancies & NHL	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-102	**Phase 1**	NCT04883957	B-Cell Malignancies	64 (CN)	-	TEAEs, MTD	Maintenance
BGB-11417-103	**Phase 1**	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	**Phase 1**	NCT04973605	R/R MM with t(11;14)	246	Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-108	**Phase 1**	NCT06697184	B-Cell Malignancies	56	Zanubrutinib	TLS	Enrolling
BGB-11417-201	**Phase 2**	NCT05471843	R/R MCL	124	-	TEAEs, ORR	Maintenance
BGB-11417-202	**Phase 2**	NCT05479994	R/R CLL/SLL	100	-	ORR	Maintenance
BGB-11417-203	**Phase 2**	NCT05952037	R/R WM	105	Zanubrutinib	MRR	Enrolling
BGB-11417-204	**Phase 2**	NCT06637501	TN CLL (contribution of components)	94	Zanubrutinib	CR/CRi	Maintenance
BGB-11417-301 (CELESTIAL-TNCLL)	**Phase 3**	NCT06073821	TN CLL/SLL	709	Zanubrutinib	PFS	Enrolling[2]
BGB-11417-302 (CELESTIAL-RRMCL)	**Phase 3**	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Enrolling
BGB-11417-303 (CELESTIAL-RRCLL)	**Phase 3**	NCT06943872	R/R CLL/SLL	630	Obinutuzumab, Rituximab	PFS	Enrolling

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Global Last Subject Enrolled completed with separate Japan cohort enrollment
Refer to Glossary abbreviations

BGB-16673 BTK CDAC

Potential first-in-class BTK degrader

As of: 23 Oct 2025

Trial	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-101 (CaDAnCe 101)	**Phase 1/2**	NCT05006716	B-Cell Malignancies	614	-	TEAEs	Enrolling
BGB-16673-102	**Phase 1**	NCT05294731	B-Cell Malignancies	146	-	TEAEs, RP2D, ORR	Enrolling
BGB-16673-104	**Phase 1/2**	NCT06634589	B-Cell Malignancies	300	Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab	DLTs, TEAEs	Enrolling
BGB-16673-302 (CaDAnCe 302)	**Phase 3**	NCT06846671	R/R CLL/SLL (investigators choice)	250	-	PFS	Enrolling
BGB-16673-303 (CaDAnCe 303)	**Phase 3**	NCT06970743	R/R CLL/SLL (CN)	150	-	PFS	Enrolling
BGB-16673-304 (CaDAnCe 304)	**Phase 3**	NCT06973187	R/R CLL/SLL (vs pirtobrutinib)	500	-	PFS	Enrolling

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations

Phase 1 and 2– other hematology assets

As of: 23 Oct 2025

Trial	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-21447-101	**BCL2i**	**Phase 1**	NCT05828589	B-cell malignancies	112	-	DLTs, AEs, TLS	Enrolling
BG-71332-101	**BCL2i+BTKi**	**Phase 1**	NCT07141511	Healthy volunteers	24	-	Cmax, AUC	Start-up
BLINCYTO 20180257	**CD19 x CD3 BiTE®**	**Phase 2**	NCT04521231	R/R and MRD+ B-ALL	281[2]	-	DLTs, AEs, TEAs, CR	Enrolling
BLINCYTO® 20190359	**CD19 x CD3 BiTE®**	**Phase 2**	NCT06054113	Pediatric R/R B-ALL	18	-	CR	Enrolling

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Total planned enrollment, with BeOne territories included
Refer to Glossary abbreviations

TEVIMBRA®

Poised for global patient impact

As of: 23 Oct 2025

Trial	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-103	**Phase 1**	NCT06091943	SubQ Formulation	60	-	Bioavailability and Safety	Closeout
BGB-HNSCC-201	**Phase 2**	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Closeout
BGB-LC-201	**Phase 2**	NCT05635708	1L NSCLC	418	LAG3, OX40, HPK1, Chemotherapy	ORR	Closeout
BGB-A317-310 (RATIONALE-310)	**Phase 3**	NCT03967977	1L UBC	420	Chemotherapy	OS (ITT)	Enrolling
BGB-A317-314	**Phase 3**	NCT04486391	R/R cHL	123 (CN)	Chemotherapy	PFS	Closeout[3]
BGB-A317-316	**Phase 3**	NCT07043400	SubQ Formulation	351	Chemotherapy	AUC	Enrolling
BGB-A317-203	**Phase 2**	NCT03209973	R/R cHL	70	-	ORR	Approved[2]
BGB-A317-204	**Phase 2**	NCT04004221	2L UC	113	-	ORR	Approved[2]
BGB-A317-312 (RATIONALE-312)	**Phase 3**	NCT04005716	1L ES-SCLC	457	Chemotherapy	OS	Approved[4]
BGB-A317-315 (RATIONALE-315)	**Phase 3**	NCT04379635	Neo/adj NSCLC	453	Chemotherapy	MPR, EFS	Approved[4]

TEVIMBRA (tislelizumab)

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Approved only in China
[3]Indication withdrawn
[4]Approved in at least one major market, such as the US, EU, China and/or Japan
Refer to Glossary abbreviations

TEVIMBRA®

Poised for global patient impact

As of: 23 Oct 2025

Trial	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-208	**Phase 2**	NCT03419897	2L+ HCC	249	-	ORR	Approved[2]
BGB-A317-209	**Phase 2**	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150	-	ORR	Approved[2]
BGB-A317-301 (RATIONALE-301)	**Phase 3**	NCT03412773	1L HCC	684	-	OS	Approved[3]
BGB-A317-302 (RATIONALE-302)	**Phase 3**	NCT03430843	2L ESCC	513	-	OS	Approved[3]
BGB-A317-303 (RATIONALE-303)	**Phase 3**	NCT03358875	2/3L NSCLC	805	-	OS (PDL1+), OS	Approved[3]
BGB-A317-304 (RATIONALE-304)	**Phase 3**	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved[3]
BGB-A317-305 (RATIONALE-305)	**Phase 3**	NCT03777657	1L GC	997	Chemotherapy	OS	Approved[3]
BGB-A317-306 (RATIONALE-306)	**Phase 3**	NCT03783442	1L ESCC	649	Chemotherapy	OS	Approved[3]
BGB-A317-307 (RATIONALE-307)	**Phase 3**	NCT03594747	1L Sq. NSCLC	360	Chemotherapy	PFS	Approved[3]
BGB-A317-309 (RATIONALE-309)	**Phase 3**	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved[3]

TEVIMBRA (tislelizumab)

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Approved only in China
[3]Approved in at least one major market, such as the US, EU, China and/or Japan
Refer to Glossary abbreviations

Phase 1 – other solid tumor assets

As of: 23 Oct 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Ph1	NCT06120283	Solid Tumors	300	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BGB-43395-102	BGB-43395	CDK4i	Ph1	NCT06253195	Solid Tumors	33	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Maintenance
BG-68501-101	BG-68501	CDK2i	Ph1	NCT06257264	Solid Tumors	218	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C9074-101	BGB-C9074	B7-H4 ADC	Ph1	NCT06233942	Solid Tumors	227	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose Escalation
BGB-21447-102	BGB-21447	BCL2i	Ph1	NCT06756932	2L+ HR+/HER2- BC	92	BGB-43395 ± Fulvestrant	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-B455-101	BGB-B455	Claudin 6 x CD3 BsAb	Ph1	NCT06803680	Solid Tumors	90	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-60366-101	BG-60366	EGFR CDAC	Ph1	NCT06685718	Solid Tumors	93	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-58067-101	BGB-58067	PRMT5i	Ph1	NCT06589596	Solid Tumors	237	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
SHY2039-001	BG-89894	MAT2Ai	Ph1	NCT06568614	Solid Tumors	140	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BG-T187-101	BG-T187	EGFR x MET x MET TsAb	Ph1	NCT06598800	Solid Tumors	87	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C0902-101	BG-C0902	EGFR x MET x MET ADC	Ph1	NCT07181681[2]	Solid Tumors	63	-	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-C354-101	BGB-C354	B7-H3 ADC	Ph1	NCT06422520	Solid Tumors	120	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-53038-101	BGB-53038	Pan-KRASi	Ph1	NCT06585488	Solid Tumors	177	Tislelizumab, Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled
Refer to Glossary abbreviations

Phase 1 – other solid tumor assets

As of: 23 Oct 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BG-C137-101	BG-C137	FGFR2b ADC	Ph1	NCT06625593	Solid Tumors	68	-	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	Ph1	NCT06596473	Solid Tumors	21	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-B2033-101	BGB-B2033	GPC3 x 4-1BB BsAb	Ph1	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose Escalation
BGB-B3227-101	BGB-B3227	MUC1 x CD16A BsAb	Ph1	NCT06540066	Solid Tumors	75	Tislelizumab, Chemotherapy	AE, SAE, DLT, MTD, RDFE	Dose Escalation
BGB-R046-101	BGB-R046	IL-15 prodrug	Ph1	NCT06487858	Solid Tumors	74 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-A317-26808-101	BGB-26808	HPK1i	Ph1	NCT05981703	Solid Tumors	217	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Expansion
BGB-A317-A3055-101	BGB-A3055	CCR8 mAb	Ph1	NCT05935098	Solid Tumors	94	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Closeout
AMG757 20230298 (DeLLphi-308)	Tarlatamab	DLL3 x CD3 BiTE® (SubQ)	Ph1	NCT06598306	2L+ SCLC	220[2]	-	DLTs, SAEs, TEAEs	Enrolling
AMG757 20240124 (DeLLphi-310)	Tarlatamab	DLL3 x CD3 BiTE® (+B7-H3)	Ph1	NCT06898957	2L+ SCLC	200[2]	YL201	DLTs, TEAEs	Enrolling
AMG509 20180146	Xaluritamig	STEAP1 x CD3 XmAb®	Ph1	NCT04221542	mCRPC	479[2]	-	TEAEs, DLTs	Maintenance
BGB-290-102	Pamiparib	PARPi	Ph1	NCT03333915	3L+ PSOC, PROC	113	-	TEAE, SAE, ORR	Approved[3]
BGB-A317-15025-101	BGB-15025	HPK1i	Ph1	NCT04649385	Solid Tumors	157	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Closeout
BGB-24714-101	BGB-24714	SMAC Mimetic	Ph1	NCT05381909	Solid Tumors	160	Chemotherapy	AE, TEAE, SAE, DLT, MTD, RDFE, ORR	Closeout

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Total planned enrollment, with BeOne territories included
[3]Approved in at least one major market, such as the US, EU, China and/or Japan
Refer to Glossary abbreviations

Phase 2 – other solid tumor assets

As of: 23 Oct 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
ZWI-ZW25-203 (HERIZON-BTC-01)	Zanidatamab	HER2 BsAb	Ph2	NCT04466891	2L+ BTC	55	-	ORR	Approved[2]
AMG757 20230273 (DeLLphi-307)	Tarlatamab	DLL3 x CD3 BiTE®	Ph2	NCT06502977	3L+ SCLC	32 (CN)	-	ORR	Maintenance
AMG757 20240092 (DeLLphi-309) (Alt dosing)	Tarlatamab	DLL3 x CD3 BiTE®	Ph2	NCT06745323	2L SCLC	240[3]	-	ORR	Enrolling
BGB-A317-A445-201	BGB-A445	OX40 mAb	Ph2	NCT05661955	Melanoma, UC	113	Tislelizumab	ORR	Closeout
BGB-LBL-007-201	BGB-LBL-007	LAG3 mAb	Ph2	NCT05609370	MSS-CRC	113	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Closeout
BGB-LBL-007-202	BGB-LBL-007	LAG3 mAb	Ph2	NCT06010303	1L ESCC	118	Tislelizumab, Chemotherapy	ORR	Closeout

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Approved only in China
[3]Total planned enrollment, with BeOne territories included
Refer to Glossary abbreviations

Phase 3 – other solid tumor assets

As of: 23 Oct 2025

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20240178 (DeLLphi-312) (Induction + Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT07005128	1L ES-SCLC	330[2]	Durvalumab +chemo (induction); Durvalumab (maintenance)	OS	Enrolling
AMG757 20200041 (DeLLphi-305) (Maintenance)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT06211036	1L ES-SCLC	550[2]	Durvalumab (maintenance)	OS	Maintenance
AMG757 20230016 (DeLLphi-306)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT06117774	LS-SCLC	400[2]	-	PFS	Enrolling
AMG757 20210004 (DeLLphi-304)	Tarlatamab	DLL3 x CD3 BiTE®	Ph3	NCT05740566	2L SCLC	509[2]	-	OS	Maintenance
BGB-A317-290-LTE1	Internal assets	Multiple	Ph3	NCT04164199	Multiple	430[3]	Multiple	Immune mediated adverse events	Enrolling
ZWI-ZW25-301 (HERIZON-GEA-01)	Zanidatamab	HER2 BsAb	Ph3	NCT05152147	1L HER2+ GEA	439	Tislelizumab ± chemo	PFS, OS	Maintenance
BGB-290-302	Pamiparib	PARPi	Ph3	NCT03519230	2L PSOC	224	-	PFS	Maintenance
BGB-A317-A1217-302 (AdvanTIG-302)	Ociperlimab	TIGIT mAb	Ph3	NCT04746924	1L NSCLC (PDL1 H)	669	Tislelizumab	OS	Closeout

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
[2]Total planned enrollment, with BeOne territories included
[3]Current planned enrollment
Refer to Glossary abbreviations

Immunology and inflammation assets

As of: 23 Oct 2025

Trial	MOA	Phase	CT.gov	Population	Total Patients[1]	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-107	BTK CDAC	Ph1	NCT07005713	Chronic spontaneous urticaria (CSU)	27	-	Incidence and severity of TEAE	Enrolling
BGB-3111-309	BTKi	Ph2/3	NCT05707377	Primary Membranous Nephropathy	282	-	Urine Protein Creatinine Ratio, Complete Remission	Enrolling
BGB-45035-101	IRAK4 CDAC	Ph1	NCT06342713	Healthy volunteers and patients with atopic dermatitis or prurigo nodularis	211	-	Incidence and severity of TEAE	Enrolling
BGB-45035-201	IRAK4 CDAC	Ph2	NCT07100938	Adults with moderate to severe active rheumatoid arthritis	90	-	Change from baseline in Disease Activity Score - C-reactive protein (DAS28-CRP) at Week 12	Enrolling

[1]Enrollment numbers represent planned enrollment for ongoing trials or actual enrollment for maintenance, close-out, or approved trials
Refer to Glossary abbreviations

Full list of commercial and clinical assets

Commercial

Product	Commercial Rights	Partner
BRUKINSA® (zanubrutinib)	Global	-
TEVIMBRA® (tislelizumab)	Global	-
PARTRUVIX® (pamiparib)	Global	-
IMDELLTRA® (tarlatamab)[1]	China	Amgen
XGEVA® (denosumab)	China	Amgen
BLINCYTO® (blinatumomab)	China	Amgen
KYPROLIS® (carfilzomib)	China	Amgen
ZIIHERA® (zanidatamab)	China	Zymeworks /Jazz
SYLVANT® (siltuximab)	China	Recordati
QARZIBA® (dinutuximab)	China	Recordati
TAFINLAR® (dabrafenib)	China	Novartis
MEKINIST® (trametinib)	China	Novartis
VOTRIENT® (pazopanib)	China	Novartis
AFINITOR® (everolimus)	China	Novartis
ZYKADIA® (ceritinib)	China	Novartis
POBEVCY® (Avastin biosimilar)	China	Bio-Thera
BAITUOWEI® (goserelin microspheres for injection)	China	Luye Pharma

Pipeline

Asset	Latest Stage	Partner	Asset	Latest Stage	Partner
Sonrotoclax (BCL2i)	Submission	-	BG-T187 (EGFR x MET x MET TsAb)	Ph1	-
BGB-16673 (BTK CDAC)	Ph3	-	BGB-C354 (B7-H3 ADC)	Ph1	-
BG-71332 (BTKi + BCL2i)[3]	Ph1	-	BGB-R046 (IL-15 prodrug)	Ph1	-
BGB-21447 (BCL2i)	Ph1	-	BGB-26808 (HPK1i)	Ph1	-
BGB-43395 (CDK4i)	Ph1	-	BG-C0902 (EGFR x MET x MET ADC)[3]	Ph1	-
BG-C9074 (B7-H4 ADC)	Ph1	Duality Bio	BGB-53038 (Pan-KRASi)	Ph1	-
BGB-68501 (CDK2i)	Ph1	Ensem	BG-C477 (CEA ADC)	Ph1	-
BGB-A3055 (CCR8 mAb)	Ph1	-	BG-C137 (FGFR2b ADC)	Ph1	-
BG-75202 (KAT6A/Bi)[3]	Ph1	-	BGB-3227 (MUC1 x CD16A BsAb)	Ph1	-
BGB-B445 (Claudin 6 x CD3 BsAb)	Ph1	-	BGB-B2033 (GPC3x4-1BB BsAb)	Ph1	-
BG-58067 (MTA Coop PRMT5i)	Ph1	-	Xaluritamig (STEAP1 x CD3 XmAb®)[2]	Ph1	Amgen
BG-89894 (MAT2Ai)	Ph1	CSPC	BGB-45035 (IRAK4 CDAC)	Ph2	-
BG-60366 (EGFR CDAC)	Ph1	-			

[1]Amgen collaboration. BeOne has tiered mid-single digit royalties on net sales
[2]Study is being conducted in China as part of the BeOne-Amgen collaboration
[3]Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Glossary

Disease abbreviations

AD	Atopic dermatitis
AML	Acute myeloid leukemia
BP-ALL	B-precursor acute lymphocytic leukemia
BTC	Biliary tract cancer
CHL	Classic Hodgkin's lymphoma
CLL	Chronic lymphocytic leukemia
CSU	Chronic spontaneous urticaria
dMMR	Deficient DNA mismatch repair
DLBCL	Diffuse large B-cell lymphoma
ES-SCLC	Extensive stage small cell lung cancer
ESCC	Esophageal squamous cell carcinoma
FL	Follicular lymphoma
GEA	Gastroesophageal adenocarcinoma
GC	Gastric cancer
HCC	Hepatocellular carinoma
HNSCC	Head and neck squamous cell carcinoma
LS-SCLC	Limited stage small cell lung cancer
MCL	Mantle cell lymphoma
mCRPC	Metastatic castration resistant prostate cancer
MDS	Myelodysplastic syndromes
MM	Multiple myeloma
MSI-H	Microsatellite stability high
MSS CRC	Microsatellite stable colorectal cancer
MTx	Maintenance
MZL	Marginal zone lymphoma
Neo/adj	Neoadjuvant/adjuvant
NSCLC	Non-small cell lung cancer
NPC	Nasopharyngeal carcinoma
PMN	Primary membranous nephropathy
PN	Prurigo nodularis
PSR OC	Platinum sensitive recurrent ovarian cancer
R/R	Relapsed or refractory
SCLC	Small cell lung cancer
SLL	Small lymphocytic lymphoma
UC / UBC	Urinary / bladder cancer
WM	Waldenström's macroglobulinemia

Other abbreviations

ADC	Antibody drug conjugate
AE	Adverse event
BiTE®	Bi-specific T-cell engager
CDAC	Chimeric degradation activation compound
CR	Complete response
DCR	Disease control rate
DLT	Dose-limiting toxicity
DOR	Duration of response
EFS	Event free survival
HV	Healthy volunteers
IITs	Investigator-Initiated Trials
LCM	Lifecycle management
LTE	Long-term extension
mAb	Monoclonal antibody
mOR	Modified overall response
MPR	Major pathological response
MTD	Maximum tolerated dose
MTx	Maintenance
NME	New Molecular Entity
ORR	Objective response rate
OS	Overall survival
PCR	Pathologic complete response
PFS	Progression-free survival
RDFE	Recommended dose for expansion
RP2D	Recommended phase 2 dose
SAE	Severe adverse event
TEAE	Treatment emergent adverse event
TN	Treatment naïve
TsAb	Tri-specific antibody
VGPR	Very good partial response
XmAb®	XmAb is a registered trademark of Xencor, Inc.